Outsourcing Facilities Association sues FDA over tirzepatide shortage delisting

The Outsourcing Facilities Association (OFA), the trade group representing 503B outsourcing facilities, filed suit against the U.S. Food and Drug Administration on October 8, 2024, over what it called the "sudden removal" of tirzepatide from the agency's drug shortage list.^[1] Tirzepatide is the active ingredient in Eli Lilly's diabetes drug Mounjaro and its obesity drug Zepbound.

The case was filed in the U.S. District Court for the Northern District of Texas.^[1] It is the opening move in litigation that will help decide whether large-scale compounding of tirzepatide copies can continue.^[1]

What the sources do and do not say

The only source available for this development is the OFA's own announcement of the lawsuit.^[1] The full text of that announcement could not be retrieved, so several details that patients would reasonably want are not yet established here: the specific legal claims the OFA is making, the exact relief it asked the court for, the date the FDA declared the tirzepatide shortage resolved, and the FDA's stated reasoning for that decision. Eli Lilly's position and any response from the FDA are also not contained in the available source material.

What is clear from the announcement is the core dispute: the FDA removed tirzepatide from its shortage list, and the trade group for outsourcing facilities went to federal court to challenge that removal.^[1] The group characterized the removal as sudden.^[1]

Why it matters for patients

The shortage list is not just an information service. Its status has direct consequences for which pharmacies and facilities can make and sell copies of a brand-name drug, and it is the hinge that this lawsuit turns on.^[1] That is why a trade association, rather than a patient group or a manufacturer, is the plaintiff.

For people who have been getting compounded tirzepatide rather than branded Mounjaro or Zepbound, the practical question is supply. If the FDA's delisting stands, the legal basis for widespread compounding of tirzepatide narrows. If the court sides with the OFA, that basis may be preserved, at least for a time. The available source does not say how quickly a ruling would come or whether the group sought an emergency order to pause the FDA's decision while the case proceeds.^[1]

It is also worth separating the two products. Compounded tirzepatide is not the same as FDA-approved Mounjaro or Zepbound. Compounded versions are not reviewed by the FDA for safety, effectiveness, or manufacturing quality in the way approved products are. The sources here do not address quality or safety findings, so nothing in this filing should be read as a statement about either.

Pricing is another practical angle the source does not cover. Many patients turned to compounded versions because of cost or because they could not find branded supply. Whether branded supply is now reliable enough to absorb that demand is not addressed in the available source material.

What happens next

The lawsuit was filed October 8, 2024, in the Northern District of Texas.^[1] No hearing dates, briefing schedule, or decision timeline appear in the available source. Patients using compounded tirzepatide, and the clinics and telehealth companies that supply it, will be watching the docket, because the availability of those products depends on how the court treats the FDA's shortage-list decision.^[1]

Anyone with questions about their own prescription or supply should raise them with the clinician or pharmacy that provides it.